Global+AI+Organ Regeneration Platform+Medical Device=ROKIT Healthcare

■ Company Overview: AI Hyper-Personalized Skin & Organ Regeneration Platform Company

ROKIT Healthcare has established an AI-based precision hyper-personalized skin and organ regeneration platform by integrating AI wound modeling, hyper-personalized bioink, FDA/CE-MDR/MFDS-approved disposable medical regeneration kits, and medical 3D bioprinters. The company successfully completed its technical-track IPO on May 12, 2025.

■ 1H 2025 Results: Revenue KRW 9.71 billion (+40.6% YoY), Operating Loss KRW 0.19 billion (+88.7% YoY)

In the first half of 2025, the company recorded revenue of KRW 9.71 billion (+40.6% YoY) and an operating loss of KRW 0.19 billion (+88.7% YoY).
Notably, in Q2 2025 —the first quarter following the IPO— ROKIT achieved an operating profit of KRW 0.06 billion, marking a turnaround to profitability.
This demonstrates that profitability has significantly improved as its global expansion and AI-driven hyper-personalized organ regeneration platform business achieved stable growth.

■ Key Checkpoints: (1) Convergence of Bio & AI Technologies, (2) Global Expansion of the Skin Regeneration Platform and Indication Pipeline ( Cartilage, Kidney, etc. )

1) Focus on Bio-AI Convergence Technology
Built upon three core technologies — ① bioink formulation, ② AI-driven automatic lesion modeling, and ③ a proprietary regeneration-niche mechanism — ROKIT Healthcare became the first in the world to commercialize an AI hyper-personalized skin and organ regeneration platform.
This innovative technology overcomes the limitations of existing therapies and is expected to pioneer a new paradigm in chronic disease treatment, particularly in the fields of skin and organ regeneration.

2) Global Strategy Focused on Expanding Skin Regeneration Platform Sales
The company’s KIT sales targets by region are prioritized as North America > South America > Middle East > Europe > Asia, with North America serving as the primary growth driver.
Leveraging insurance reimbursement coverage, ROKIT plans to partner with two major U.S. Group Purchasing Organizations (GPOs), securing access to over 9,350 hospitals.
The company also aims to increase market penetration by expanding insurance coverage across large hospital networks.
Under this strategy, global KIT sales volume in 2025 is projected to reach 7,340 units — approximately 3.2 times higher than 2024’s 2,276 units.
Further indication expansion to cartilage and kidney regeneration is also under development and expected to drive additional growth.

■ Risk Factor: Overhang Issue

In July 2025, the company issued the 9th convertible bond worth KRW 30 billion at a conversion price of KRW 16,672 per share, creating a potential overhang risk.